Study of Amylopectin Chromium Blend Effects on Protein Balance and Glucose Control in Women Aged 40-65 During Peri- and Post-Menopause

What this Trial Is About

Researchers are investigating how an amylopectin chromium blend affects whole-body protein balance in peri- and post-menopausal women aged 40 to 65. This study aims to understand if the supplement can support positive protein balance during midlife hormonal changes and whether a concentrated dose may be effective. The study also evaluates glucose control using continuous monitoring over 24 hours. Participants will be randomly assigned to one of three groups a standard dose of the amylopectin-chromium blend, a concentrated dose, or a placebo containing amylopectin alone. Each participant will consume the assigned supplement with 20 grams of yogurt protein immediately after a short resistance exercise session. A second protein serving will be taken later with an evening meal. The study includes four in-person visits over 2 to 3 weeks, including screening, baseline assessments, exercise familiarization, and the main intervention day. Throughout the study, participants will follow a controlled diet and avoid caffeine, alcohol, and strenuous exercise before visits. Researchers will collect blood and urine samples to measure protein synthesis and breakdown, using stable isotope tracers, and will monitor glucose levels continuously. Safety and tolerability will be tracked during visits. The main outcomes are changes in protein turnover and glucose control, helping to guide nutritional strategies for muscle and metabolic health in midlife women.

Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women